Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster viewing 03

143P - Clinical outcomes of systemic therapy for hemodialysis patients with metastatic renal cell carcinoma

Date

03 Dec 2022

Session

Poster viewing 03

Topics

Tumour Site

Renal Cell Cancer

Presenters

Shun Iwasa

Citation

Annals of Oncology (2022) 33 (suppl_9): S1485-S1494. 10.1016/annonc/annonc1124

Authors

S. Iwasa, R. Mizuno, Y. Yasumizu, N. Tanaka, T. Takeda, K. Matsumoto, S. Morita, T. Kosaka, H. Asanuma, M. Oya

Author affiliations

  • Department Of Urology, Keio University School of Medicine, 160-8582 - Shinjuku-ku/JP

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 143P

Background

The prognosis of patients with metastatic renal cell carcinoma (mRCC) has improved markedly with the introduction of molecular-targeted agents and immune checkpoint inhibitors. However, there are few reports on the outcome of systemic therapy for hemodialysis patients with mRCC. The purpose of this study is to evaluate the outcome of the systemic therapy for hemodialysis patients with mRCC.

Methods

We retrospectively studied 253 patients with mRCC (17 hemodialysis patients and 236 non-dialysis patients) treated with systemic therapy at Keio University Hospital in Japan. A progression-free survival (PFS) and overall survival (OS) were evaluated by Kaplan-Meier method.

Results

The pathological diagnosis of the clear cell carcinoma was 52.9% in hemodialysis patients and 82.6% in non-dialysis patients (p=0.007). Hemodialysis patients (10 intermediate risk; 7 poor risk) received first line therapy; 4 received cytokine therapy, 11 received tyrosine kinase inhibitor, 1 received mTOR inhibitor, and 1 received immune checkpoint inhibitor. A median PFS was 6.9 months for hemodialysis patients and 17.0 months for non-dialysis patients (p<0.001), and median OS was 21.2 months for hemodialysis patients and 49.4 months for non-dialysis patients (p<0.001), respectively.

Conclusions

PFS and OS were significantly shorter in hemodialysis patients with mRCC compared to non-dialysis patients.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.